Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Spotlight

About Prescrire

• Who are we?
• How we work
• AMP: non-profit
• Financing
• "Non merci"
• Where to find us
• About Prescrire International
• Testimonials
• Prescrire events
• A global network

Offers

• Subscribe now
• Solidarity Subscription Rate
• Refer a friend or colleague
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

Prescrire's other websites

In Prescrire's Spotlight

New special section: "Mediator° - the criminal trial" The independent French medical journal Prescrire began asking questions about the appetite-suppressant drug Mediator° (benfluorex) in 1986, and called for its withdrawal some 12 years before the French authorities finally took action. Meanwhile thousands of patients suffered serious, sometimes fatal, adverse effects. As the criminal trial opens in France, Prescrire looks back over the disaster, and analyses just what is at stake. 09 October 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Axicabtagene ciloleucel (Yescarta°) in certain types of lymphoma when other treatment options have been exhausted FEATURED REVIEW Axicabtagene ciloleucel  is a CAR (chimeric antigen receptor) T-cell therapy. It increases the chances of survival in certain situations but frequently provokes serious adverse effects. There is a pressing need for more thorough clinical evaluation. Full review (3 pages) available for download by subscribers. 1 October 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ In the October issue of Prescrire International: clear shortcomings in the independence of French medical schools FREE DOWNLOADInvestigation by a nonprofit organisation revealed poor application of a charter signed by deans of French medical and dental schools. Full text available for free download. 1 October 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯   The 2019 "Prescrire Prize" is awarded in Paris to   3 noteworthy books about health and healthcare The recipients of the 2019 "Prescrire Prize" book awards were announced on 3 October 2019. The prize is awarded to works of particular interest to the general public and/or healthcare professionals. 03 October 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ "Faces of Mediator", a new book published by Prescrire It was after seeing the French film "La Fille de Brest", an adaptation of the book by pulmonologist and whistle-blower Irène Frachon, that the photographer Marc Dantan first got the idea of taking portraits of the victims of Mediator° (benfluorex), in the hope that "bringing faces into the light could perhaps raise awareness of the silent suffering". That was the beginning of this book, which presents in 208 pages some 180 photographs, along with a foreword by Irène Frachon, a summary of the history of the Mediator° disaster, and an afterword by Prescrire. Texts in French and English. 1 October 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Secondary cardiovascular prevention: dubious benefits of evolocumab (Repatha°) and alirocumab (Praluent°) In patients who have already had a cardiovascular event, the addition of evolocumab or alirocumab to a statin does not reduce mortality but does expose to adverse effects, although these are not well known. 1 October 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Paracetamol: patients need to be more aware of the harms In France, 20% of patients seem to be unaware that paracetamol is toxic at high doses, especially to the liver, and around 30% are unaware that alcohol aggravates this toxicity. 1 October 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Trials funded by drug companies: publication or publicity? Pharmaceutical companies have a tight grip on the publication of the clinical study results that will allow them to obtain marketing authorisation for their products. A situation that is regrettable, but predictable. 1 October 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drug-device combinations: EMA's consultation on quality requirements is an opportunity to strengthen patient safety  ADVANCING HEALTHCARE POLICY  Drug-device combinations play a major role in preventing medication errors. EMA's public consultation is an opportunity for EMA to significantly strengthen its expertise in these health products and patient safety. Prescrire offers a series of recommendations mainly aimed at protecting children, elderly patients, and patients undergoing high-risk hospital care. 30 August 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON Dolutegravir + rilpivirine dual therapy in HIV infection • Gemtuzumab ozogamicin in acute myeloid leukaemia • Fenspiride: serious adverse effects that took a very long time to be taken into account • Diabetes and primary prevention of cardiovascular disease • New drugs: the key role of publicly-funded research in the United States... > Subscribe now 1 October 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International Subscribe now Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries). 1 December 2018

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ "Top Texts of 2019", new from the editors of Prescrire International  NEW: FREE SPECIAL EDITION  Check out this brand new sampling of texts selected by our editors to introduce you to Prescrire International, a wholly independent monthly journal, written by and for healthcare professionals 28 August 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 September 2018

• Sitemap |
• Terms of use |
• Contact
• |Top of page